secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097206
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon restates financials due to warrant misclassification; reports $83.6M cash and Phase 2 progress
--------------------------------------------------------------------------------

- Non-reliance on FY2023 and Q1 2024 financials due to warrant derivative accounting error; expects restatement and amendments.
- Ended Q2 with $83.6M cash, including $50M private placement; expects liquidity through December 2025.
- Phase 2 BESTOW trial enrolled 80th participant, on track to complete enrollment by end of 2024.
- Phase 1b data from 13 kidney transplant patients showed mean eGFR 70.5; two patients >90 at one year.
- Identified material weakness in internal control over financial reporting; restatement is non-cash and does not affect operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024097206/0000950170-24-097206-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017024097206/eldn-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097206

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer